相似文献/References:
[1]陈馨仪,符 晓,王安石,等.罕见病患者治疗及保障研究[J].卫生经济研究,2020,(09):40.
CHEN Xin-yi,FU Xiao,WANG An-shi,et al.Research on the Treatment and Guarantee of Patients with Rare Diseases[J].Journal Press of Health Economics Research,2020,(05):40.
[2]王子琪,闵连星,田兴军,等.我国罕见病医保政策的现状及优化路径[J].卫生经济研究,2021,38(11):22.
WANG Zi-qi,MIN Lian-xing,TIAN Xing-jun,et al.The Situation and Optimization Path of Medical Insurance Policy for Rare Diseases in China[J].Journal Press of Health Economics Research,2021,38(05):22.
[3]陈子梦,王 丽,章 浴,等.基于供应链理论的我国孤儿药可及性分析与建议[J].卫生经济研究,2022,39(6):55.
CHEN Zimeng,WANG Li,ZHANG Yu,et al.Analysis and Suggestions on the Accessibility of Orphan Medicines in China Based on Supply Chain Theory[J].Journal Press of Health Economics Research,2022,39(05):55.
[4]李诗杨,殷彩琴,周 楠,等.“互联网+”背景下孤儿药可及性提升策略研究——基于长尾效应[J].卫生经济研究,2022,39(9):49.
LI Shiyang,YIN Caiqin,ZHOU Nan,et al.Study on the Strategy of Improving the Accessibility of "Internet +" Orphan Drug——Based on the Long Tail Effect[J].Journal Press of Health Economics Research,2022,39(05):49.
[5]张永理,张开然.我国罕见病患者医疗保障现状及改进建议[J].卫生经济研究,2023,40(1):53.
ZHANG Yongli,ZHANG Kairan.Medical Security Status and Improvement Suggestions for Patients with Rare Diseases in China[J].Journal Press of Health Economics Research,2023,40(05):53.
[6]朱 坤sup>.中国罕见病保障机制：现状、挑战与建议[J].卫生经济研究,2024,41(01):23.
ZHU Kun.Security Mechanism for Rare Diseases in China: Progress，Problems and Suggestions[J].Journal Press of Health Economics Research,2024,41(05):23.
[7]谭清立,丘丽莹.城市普惠型商业医疗保险比较研究[J].卫生经济研究,2024,41(02):23.
TAN Qingli,QIU Liying.Comparative Study on Urban Inclusive Commercial Medical Insurance[J].Journal Press of Health Economics Research,2024,41(05):23.
[8]林 星,董田甜.罕见病药品保障模式的国际经验与启示
——以酶替代疗法药品为例[J].卫生经济研究,2024,41(11):54.
LIN Xing,DONG Tiantian.International Experience and Enlightenment of Drug Security Model for Rare Diseases
——Taking Enzyme Replacement Therapy Drugs as an Example[J].Journal Press of Health Economics Research,2024,41(05):54.
[9]沈杨阳.中国罕见病问题及综合保障机制研究[J].卫生经济研究,2024,41(12):1.
SHEN Yangyang.Study on the Problems of Rare Diseases and Comprehensive Protection Mechanisms in China[J].Journal Press of Health Economics Research,2024,41(05):1.
[10]刘慧玲,赵恒伯,谢志勤,等.2022年江西省罕见病治疗费用核算分析
——基于SHA2011[J].卫生经济研究,2025,42(02):46.
LIU Huiling,ZHAO Hengbo,XIE Zhiqin,et al.Analysis of Rare Disease Treatment Cost Accounting in Jiangxi Province in 2022
——Based on SHA2011[J].Journal Press of Health Economics Research,2025,42(05):46.
[11]李奕昊,唐贵忠.罕见病用药可负担性评价及医保政策研究[J].卫生经济研究,2022,39(4):53.
LI Yi-hao,TANG Gui-zhong.Affordability Evaluation of Drugs for Rare Diseases and Research on Medical Insurance Policy[J].Journal Press of Health Economics Research,2022,39(05):53.
[12]王珺琦,殷 悦,唐文熙.医保准入视角下罕见病用药经济价值评估的
难点、方法与建议[J].卫生经济研究,2024,41(09):58.
WANG Junqi,YIN Yue,TANG Wenxi.Difficulties, Methods, and Suggestions for Assessing the Economic Value
of Rare Disease Medications from the Perspective of Health Insurance Access[J].Journal Press of Health Economics Research,2024,41(05):58.